Bioequivalence and Bioavailability Forum 23:12 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

95% Upper bound calculation [RSABE / ABEL]

posted by Katrin_Ti - Austria, 2018-03-13 09:31  - Posting: # 18526
Views: 821

Hi,

as the guidence for acyclovir creams defines:

The replicate skin sections from donor 1 dosed with the test product may be denoted as T11,
T21, ..., Tr1, and likewise from donor 2, T12, T22, ..., Tr2, and so forth up to n donors; T1n,
T2n, ..., Trn. Similarly, the replicate skin sections dosed with the RLD product may be denoted as R1n, R2n, ..., Rrn.



That means that you need the same number of replicates from each donor (for R and T) for further calculations.

Calculate the point estimate, inter-donor variability and within reference variability using the log-transformed data (as defined in the acyclovir cream guidance).
If SWR >= 0.294 use the RSABE approach and calculate the upper bound of the CI as described in the Progesterone guidance.
I think the SAS code described in the progesterone guidance has to be modified but I can not help you with this task.

Greetings

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,923 posts in 4,039 threads, 1,285 registered users;
online 9 (1 registered, 8 guests [including 4 identified bots]).

Whenever you find that you are on the side of the majority,
it is time to pause & reflect.    Mark Twain

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed